A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

257

Participants

Timeline

Start Date

February 5, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
Diabetes Type 2Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseaseEndocrine System Diseases
Interventions
DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (25)

100005

Beijing Hospital, Beijing

101200

Beijing Pinggu District Hospital, Beijing

150001

The First Hospital of Harbin Medical University, Harbin

The Fourth Hospital of Harbin Medical University, Harbin

210006

Nanjing First Hospital, Nanjing

210009

Zhongda Hospital Southeast University, Nanjing

210011

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

212000

Affiliated Hospital of Jiangsu University, Zhenjiang

213000

Changzhou No.2 People's Hospital, Changzhou

214023

Wuxi People's Hospital, Wuxi

214400

The Affiliated Jiangyin Hospital of Southeast University Medical College, WuxiShi

230011

The Second People's Hospital of Hefei, Hefei

250013

Jinan Central Hospital, Jinan

300052

Tianjin Medical University General Hospital, Tianjin

313000

Huzhou Central Hospital, Huzhou

330009

The Third Hospital of Nanchang, Nanchang

400014

Chongqing General Hospital, Chongqing

414000

The First People's Hospital of Yueyang, Yueyang

450014

The Second Affiliated Hospital of Zhengzhou University, Zhengzhou

471003

The First Affiliated Hospital of Henan University of Science &Technology, LuoyangShi

516001

Huizhou Municipal Central Hospital, Huizhou

610041

West China Hospital of Sichuan University, Chengdu

611130

Chengdu Fifth People's Hospital, Chengdu

710077

The First Affiliated Hospital of Xi'an Medical University, Xi'an

014040

Baotou Central Hospital, Baotou

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY